CDI said in a statement on Wednesday it has signed a
long-term agreement to supply stem cells to the Nestle Institute of
Health Sciences. Financial terms of the deal were not disclosed.
Nestle is increasingly linking up food and science with its Health
Science unit, set up in 2011 to pursue a growing demand for "medical
foods" from an ageing population.
Last February, Nestle said it would buy U.S. company Pamlab, which
makes such foods for patients with conditions including diabetic
peripheral neuropathy, dementia, depression and high-risk pregnancy.
That deal followed the purchase in 2012 of a stake in U.S. firm
Accera, which makes a medical food brand for Alzheimer's patients.
CDI develops and manufactures human cells in industrial quantities
to precise specifications for research customers.
[to top of second column]
The Wall Street Journal said earlier that Nestle would use the
cells to study the effect of nutrients found in foods and develop
nutritionally enhanced drinks and other products.
(Reporting by Caroline Copley; editing
by Greg Mahlich)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.